Exact Mass: 476.01195780000006
Exact Mass Matches: 476.01195780000006
Found 48 metabolites which its exact mass value is equals to given mass value 476.01195780000006
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Cefazolin sodium
C14H13N8NaO4S3 (476.01195780000006)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
Ebrotidine
Ebrotidine is an H2 receptor antagonist with gastroprotective activity against ethanol-, aspirin- or stress-induced gastric mucosal damage. The antisecretory properties of ebrotidine are similar to those of ranitidine, and approximately 10-fold greater than those of cimetidine. Ebrotidine has anti-Helicobacter pylori activity via inhibition of the urease enzyme and the proteolytic and mucolytic activities of the bacterium. However, its activity is synergistic with a number of antibacterial agents. Ebrotidine counteracts the inhibitory effects of H. pylori lipo-polysaccharides. C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Ebrotidine(FI 3542) is a competitive H2-receptor antagonist (Ki= 127.5 nM) with a potent antisecretory activity and evidenced gastroprotection. IC50 Value: 127.5 nM (Ki)[1]; 0.21mg/kg (ED50, histamine- stimulated acid secretion) [2] Target: H2 receptor in vitro: Ebrotidine displaced 3H-thiotidine specific binding to histamine H2-receptors (Ki: 127.5 nmol/l), showing a higher affinity (p < 0.05) than ranitidine (Ki: 190.0 nmol/l) and cimetidine (Ki: 246.1 nmol/l) [1]. in vivo: Following intravenous administration to rats, ebrotidine inhibited histamine- and pentagastrin-stimulated acid secretion in a dose-dependent manner, ED50 being 0.21 and 0.44 mg/kg, respectively [2]. The mean number of gastric erosions seen at endoscopy after treatment with ebrotidine plus ASA (2.0 +/- 0.3) was significantly lower than that after placebo plus ASA (3.7 +/- 0.2). This reduction in lesion core by ebrotidine was accompanied by a significant increase in gastric blood flow (by 15\% in corpus and 26\% in antrum), by a rise in transmucosal potential difference (by 12\%), and by a decrease of mucosal microbleeding [3]. Results of macroscopic assessment revealed that ebrotidine at doses of 50mg and higher/kg body weight effectively prevented mucosal injury, and that the maximal protective effect was achieved by 1h. Physicochemical analysis established that ebrotidine evoked 30\% increase in mucus gel dimension, and showed 20\% increase in phospholipids, and the content of sulfo- (18\%) and sialomucins (21\%) [4].
Ellagic acid acetyl-xyloside
Ellagic acid acetyl-xyloside is a member of the class of compounds known as hydrolyzable tannins. Hydrolyzable tannins are tannins with a structure characterized by either of the following models. In model 1, the structure contains galloyl units (in some cases, shikimic acid units) are linked to diverse polyol carbohydrate-, catechin-, or triterpenoid units. In model 2, contains at least two galloyl units C-C coupled to each other, and do not contain a glycosidically linked catechin unit. Ellagic acid acetyl-xyloside is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Ellagic acid acetyl-xyloside can be found in red raspberry, which makes ellagic acid acetyl-xyloside a potential biomarker for the consumption of this food product.
Ellagic acid acetyl-arabinoside
Ellagic acid acetyl-arabinoside is a member of the class of compounds known as hydrolyzable tannins. Hydrolyzable tannins are tannins with a structure characterized by either of the following models. In model 1, the structure contains galloyl units (in some cases, shikimic acid units) are linked to diverse polyol carbohydrate-, catechin-, or triterpenoid units. In model 2, contains at least two galloyl units C-C coupled to each other, and do not contain a glycosidically linked catechin unit. Ellagic acid acetyl-arabinoside is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Ellagic acid acetyl-arabinoside can be found in red raspberry, which makes ellagic acid acetyl-arabinoside a potential biomarker for the consumption of this food product.
Rhamnetin 3,3-disulfate
2,6-Bis(2,2,2-trifluoroethoxy)-3-{[3-(trifluoromethyl)-2-pyridyl]thio}benzonitrile
C17H9F9N2O2S (476.02410019999996)
(2R,3S,4R,5S,6S,7R)-2,3,5,6,7-pentachloropentadec-14-en-4-yl hydrogen sulfate
C15H25Cl5O4S (475.9916120000001)
3,4-dioxoloellagic acid 4-glucoside|3,4-methylene-4-O-beta-D-glucopyranosylellagic acid|3,4-methylenedioxyellagic acid 4-O-beta-D-glucopyranoside|okicamelliaside
Ebrotidine
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Ebrotidine(FI 3542) is a competitive H2-receptor antagonist (Ki= 127.5 nM) with a potent antisecretory activity and evidenced gastroprotection. IC50 Value: 127.5 nM (Ki)[1]; 0.21mg/kg (ED50, histamine- stimulated acid secretion) [2] Target: H2 receptor in vitro: Ebrotidine displaced 3H-thiotidine specific binding to histamine H2-receptors (Ki: 127.5 nmol/l), showing a higher affinity (p < 0.05) than ranitidine (Ki: 190.0 nmol/l) and cimetidine (Ki: 246.1 nmol/l) [1]. in vivo: Following intravenous administration to rats, ebrotidine inhibited histamine- and pentagastrin-stimulated acid secretion in a dose-dependent manner, ED50 being 0.21 and 0.44 mg/kg, respectively [2]. The mean number of gastric erosions seen at endoscopy after treatment with ebrotidine plus ASA (2.0 +/- 0.3) was significantly lower than that after placebo plus ASA (3.7 +/- 0.2). This reduction in lesion core by ebrotidine was accompanied by a significant increase in gastric blood flow (by 15\% in corpus and 26\% in antrum), by a rise in transmucosal potential difference (by 12\%), and by a decrease of mucosal microbleeding [3]. Results of macroscopic assessment revealed that ebrotidine at doses of 50mg and higher/kg body weight effectively prevented mucosal injury, and that the maximal protective effect was achieved by 1h. Physicochemical analysis established that ebrotidine evoked 30\% increase in mucus gel dimension, and showed 20\% increase in phospholipids, and the content of sulfo- (18\%) and sialomucins (21\%) [4].
(4-Bromobutyl)(triphenyl)phosphonium bromide
C22H23Br2P (475.99040080000003)
sodium,formaldehyde,2-hydroxybenzenesulfonate,4-(4-hydroxyphenyl)sulfonylphenol
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[4-[6-(1,2,4-oxadiazol-3-yl)pyrimidin-4-yl]oxyphenyl]urea
C20H12ClF3N6O3 (476.06114679999996)
PH-797804
C22H19BrF2N2O3 (476.0547028000001)
(R,R)-1,2-Bis(Trifluoromethanesulfonamido)-1,2-Diphenylethane
C16H14F6N2O4S2 (476.02991560000004)
6,13-dibromo-9,10-dimethoxy-1a,2,3,4,4a,5-hexahydro-1H-indeno[2,1-d]fluorene
C22H22Br2O2 (475.99864319999995)
Sitaxentan sodium
C18H14ClN2NaO6S2 (475.98794940000005)
Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is an orally active, highly selective antagonist of endothelin A receptors.
[[[1-[5-[2-Chloro-4-(trifluoromethyl)phenoxy]-2-nitrophenyl]-2-methoxyethylidene]amino]oxy]acetic acid methyl ester
(3-BROMOBUTYL)TRIPHENYLPHONIUM BROMIDE
C22H23Br2P (475.99040080000003)
1H,1H,2H,3H-PERFLUOROUNDEC-2-EN-1-OL
C11H5F17O (476.00689239999997)
bis(chlorophenyl)phenylsulphonium hexafluorophosphate(1-)
C18H13Cl2F6PS (475.97568000000007)
N,N-((1S,2S)-1,2-DIPHENYLETHANE-1,2-DIYL)BIS(1,1,1-TRIFLUOROMETHANESULFONAMIDE)
C16H14F6N2O4S2 (476.02991560000004)
(η-cumene)-(η-cyclopentadienyl)iron(II) hexafluoroantimonate
sodium,formaldehyde,4-hydroxybenzenesulfonic acid,4-(4-hydroxyphenyl)sulfonylphenolate
Benzamide, N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-((4-iodo-2-methylphenyl)amino)-
C18H16F3IN2O2 (476.02085819999996)
[10-(4-chlorophenyl)-2,6,8-trioxo-3,4a,5,5a,6,8,8a,9,9a,10-decahydro-5,9-methano[1,3]thiazolo[5,4:5,6]thiopyrano[2,3-f]isoindol-7(2H)-yl]acetic acid
2-({4-[(5-Chloro-1H-indol-2-YL)sulfonyl]piperazin-1-YL}carbonyl)thieno[3,2-B]pyridine 4-oxide
(2S,3S,4S,5R,6S)-6-[4-(5,7-dihydroxy-3-oxido-4-oxochromen-2-yl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylate
4-Bromo-3-(carboxymethoxy)-5-[4-[[oxo(3-pyridinyl)methyl]amino]phenyl]-2-thiophenecarboxylic acid
C19H13BrN2O6S (475.96776580000005)
N-[2-[(5Z)-2,4-dioxo-5-(pyridin-3-ylmethylidene)-1,3-thiazolidin-3-yl]ethyl]-4-methylsulfonyl-3-nitrobenzamide
2-[(2Z)-2-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]methylidene]-4-oxo-1,3-thiazolidin-3-yl]-N-(2-chloropyridin-3-yl)acetamide
C20H14Cl2N4O2S2 (475.99352039999997)